Corcept Therapeutics Incorporated
NASDAQ:CORTBiotechnology
-$1.96 today
- Market cap
- $7.42B
- Beta
- 0.50
- P/E (TTM)
- 178.2
- EPS (TTM)
- $0.46
Volume 0.74M
Average 1.41M
CORT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Corcept Therapeutics IncorporatedNASDAQ: CORT
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $42.99M rose 22.3% year over year, ahead of the -3.0% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Net income amounted to 12.9% of revenue in FY2025, down 8.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $287.71M (+193.1%) for the fiscal year ending Dec 2026, a step up from the -30.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $42.99M+235.3% QoQ
- Last fiscal yearDec 2025
- $98.17M-30.5% YoY
- LTMJun 2026
- $128.76M-3.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 98.17M USD
- Year-over-year change
- -30.5%
- 4-year CAGR
- -3.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.17M | -30.5% |
| FY2024 | 2024-12-31 | 141.21M | +33.0% |
| FY2023 | 2023-12-31 | 106.14M | +4.7% |
| FY2022 | 2022-12-31 | 101.42M | -9.9% |
| FY2021 | 2021-12-31 | 112.51M | — |
Net Income vs competitors
How CORT compares with its peers on the latest reported figures
- CORT's LTM Jun 2026 net income of $128.76M is the 2nd largest of the 3 companies compared; the peer median is $91.14M.
- Its year-over-year change of -3.0% is the 2nd highest of 3, against a peer median of +23.7%.
- Net income amounts to 15.5% of revenue for CORT.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $145.1M | +80.3% | +49.3% | — |
| LTM Jun 2026 | $128.76M | -3.0% | -1.1% | 15.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| Peer median (excluding CORT) | $91.14M | +23.7% | +21.9% | — | |
Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 112.51M | 101.42M | 106.14M | 141.21M | 98.17M |
| Depreciation & Amortization | 3.07M | 3.45M | 2.36M | 1.34M | 1.89M |
| Deferred Income Tax | 4.35M | (33.91M) | (29.49M) | (40.19M) | 0 |
| Stock-Based Compensation | 42.93M | 42.44M | 48.94M | 61.35M | 84.5M |
| Change in Working Capital | (57K) | 5.54M | 8.22M | 45.3M | (27.57M) |
| Accounts Receivables | (1.43M) | (17.43M) | (10.07M) | 1.15M | (5.81M) |
| Inventory | 3.44M | 1.2M | 1.27M | 305K | (7.48M) |
| Accounts Payables | (3.6M) | 4.76M | 5.78M | (2.25M) | 25.07M |
| Other Working Capital | 1.52M | 17.02M | 11.24M | 46.09M | (39.34M) |
| Other Non-Cash Items | 5.09M | 1.38M | (9.13M) | (10.94M) | (15M) |
| Operating Cash Flow | 167.89M | 120.32M | 127.04M | 198.07M | 142M |
| Capital Expenditures | (469K) | (413K) | (139K) | (2.17M) | (211K) |
| Acquisitions (Net) | (136.6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (312.81M) | (355.07M) | (328.75M) | (588.31M) | (319.61M) |
| Sales of Investments | 449.4M | 241.15M | 419.79M | 412.88M | 389.58M |
| Other Investing Activities | 136.6M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 136.13M | (114.33M) | 90.91M | (177.6M) | 69.76M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 9.62M | 0 |
| Common Stock Repurchased | (295.99M) | 0 | (145.43M) | (15.66M) | (245.86M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.61M) | (17.28M) | (3.3M) | (22.3M) | 25.49M |
| Financing Cash Flow | (302.59M) | (17.28M) | (148.72M) | (28.35M) | (220.37M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 1.44M |
| Net Change in Cash | 1.43M | (11.29M) | 69.22M | (7.89M) | (7.17M) |
| Free Cash Flow | 167.42M | 119.91M | 126.9M | 195.9M | 141.79M |
Corcept Therapeutics Incorporated
NASDAQ:CORT
Intrinsic Alpha fair value
Locked
Current Price
$67.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.